Mammary Cell News 9.40 October 12, 2017 | |
| |
TOP STORYResearchers showed that knockout of phospholipase D2 (PLD2), which generates the signaling lipid phosphatidic acid, inhibits lung metastases in the mammary tumor virus-Neu transgenic mouse breast cancer model. [Dev Cell] Full Article | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Slug/Pcad Pathway Controls Epithelial Cell Dynamics in Mammary Gland and Breast Carcinoma Scientists found that Slug unexpectedly binds and activates P-cadherin (Pcad) promoter through E-boxes, inducing Pcad expression. They determined that Pcad could mediate several functions of Slug: Pcad promoted clonal mammosphere growth, basal epithelial differentiation, cell–cell dissociation and cell migration, rescuing Slug depletion. [Oncogene] Abstract Investigators observed that high serum resistin levels in breast cancer patients positively correlated with tumor stage, size and lymph node metastasis. [Oncogene] Abstract To investigate the function of ADAM8 in metastasis, MB-231 breast cancer cells with ADAM8 knockdown and scramble control cells were analyzed for their capability to develop metastases. In vitro, formation of metastatic complexes in hanging drops is dependent on ADAM8 and blocked by ADAM8 inhibition. [Int J Cancer] Abstract Researchers determined the effect of eugenol on cellular energy metabolism during early cancer progression employing untransformed and H-ras oncogene transfected MCF10A human breast epithelial cells. [Sci Rep] Full Article Scientists profiled extracellular vesicles harvested from therapeutic induced senescent (TIS) triple negative breast cancer (TNBC) cells compared with control cells to identify a potential mechanism by which TIS TNBC cells maintain survival in the face of chemotherapy. TIS was induced and confirmed in Cal51 TNBC cells using the chemotherapeutic paclitaxel. [Oncogenesis] Full Article Vertical Inhibition of the PI3K/Akt/mTOR Pathway Is Synergistic in Breast Cancer Investigators evaluated the effects of vertical inhibition of mechanistic target of rapamycin (mTOR) and Akt in breast cancer cell lines and xenografts. They assessed the effects of mTOR inhibitor rapamycin and Akt inhibitor MK-2206, given as single drugs or in combination, on cell signaling, cell proliferation and apoptosis in a panel of cancer cell lines in vitro. [Oncogenesis] Full Article The authors evaluated the chemistry, cytotoxicity and metabolomics of an organic extract from the Mediterranean marine sponge Geodia cydonium, collected in coastal waters of the Gulf of Naples. They identified an active fraction able to block proliferation of breast cancer cell lines MCF-7, MDA-MB231, and MDA-MB468 and to induce cellular apoptosis, whereas it was inactive on normal breast cells (MCF-10A). [Int J Mol Sci] Full Article MicroRNA-193a Inhibits Breast Cancer Proliferation and Metastasis by Downregulating WT1 Researchers found decreased microR-193a (miR-193a) expression not only in breast cancer cell lines but also in breast cancer tissues as compared with the adjacent non-tumor tissues. Ectopic miR-193a overexpression inhibited the proliferation, colony formation, migration, and invasion of MDA-MB-231 and BT549 cells. [PLoS One] Full Article | |
| |
REVIEWSTargeting Triple Negative Breast Cancer with Histone Deacetylase Inhibitors The authors focus on the challenges so far addressed in the targeted treatment of triple negative breast cancer and explore the various mechanisms by which histone deacetylase inhibitors control cancer cell growth, tumor progression and metastases. [Expert Opin Investig Drugs] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSSeattle Genetics, Inc. announced two clinical collaboration agreements for the evaluation of SGN-LIV1A in patients with triple negative breast cancer. SGN-LIV1A is an investigational antibody-drug conjugate that targets the cell surface protein LIV-1, which is expressed on multiple solid tumors including breast, prostate, melanoma, ovarian, and cervical cancers. [Seattle Genetics, Inc.] Press Release SYNERGYS Announces Phase I SBIR Grant Award From National Institutes of Health Synergys Biotherapeutics announced the receipt of a Phase I grant from the National Cancer Institute under auspices of the Small Business Innovation Research program of the National Institutes of Health. [Synergys Biotherapeutics (Business Wire, Inc.)] Press Release Eli Lilly and Company announced that the FDA has granted Priority Review designation for its New Drug Application for Verzenioâ„¢, a cyclin-dependent kinase (CDK)4 & 6 inhibitor. [Eli Lilly and Company] Press Release | |
| |
POLICY NEWSPublishers Threaten to Remove Millions of Papers from ResearchGate Millions of articles might soon disappear from ResearchGate, the world’s largest scholarly social network. Five publishers said they had formed a coalition that would start ordering ResearchGate to remove research articles from its site because they breach publishers’ copyright. [Nature News] Editorial Navajo Nation Reconsiders Ban on Genetic Research When the Navajo Nation opens its first oncology centre next year in Tuba City, Arizona, clinicians there may be able to offer a service that has been banned on tribal lands for 15 years: analyzing the DNA of Navajo tribe members to guide treatments and study the genetic roots of disease. [Nature News] Editorial
| |
EVENTSNEW EMBL Course: Techniques for Mammary Gland Research Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Training Fellows – Breast Cancer Research (Institute of Cancer Research) Postdoctoral Fellowship – Breast Cancer Research (Geisel School of Medicine at Dartmouth) Assistant Professor – Cancer Biology (Perelman School of Medicine) Assistant Professor – Cancer Research (University of Minnesota) Postdoctoral Position – Cancer Metabolism (University of Louvain) Postdoctoral Position – Transcriptomics and Cancer Epigenetics (Universität Basel) Higher Scientific Officer – Breast Cancer Research (Institute of Cancer Research) Postdoctoral Training Fellow – Breast Cancer Research (Institute of Cancer Research) Postdoctoral Opportunities – Cancer Research (Albert Einstein College of Medicine in New York) Associate Medical Director/Medical Director – Breast Cancer (Genentech, Inc.) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|